Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.

Williams JT, Haiderer ER, Coulson GB, Conner KN, Ellsworth E, Chen C, Alvarez-Cabrera N, Li W, Jackson M, Dick T, Abramovitch RB.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00547-19. doi: 10.1128/AAC.00547-19. Print 2019 Oct.

PMID:
31405862
2.

Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.

Sarathy J, Blanc L, Alvarez-Cabrera N, O'Brien P, Dias-Freedman I, Mina M, Zimmerman M, Kaya F, Ho Liang HP, Prideaux B, Dietzold J, Salgame P, Savic RM, Linderman J, Kirschner D, Pienaar E, Dartois V.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02516-18. doi: 10.1128/AAC.02516-18. Print 2019 May.

3.

Investigation of ( S)-(-)-Acidomycin: A Selective Antimycobacterial Natural Product That Inhibits Biotin Synthase.

Bockman MR, Engelhart CA, Cramer JD, Howe MD, Mishra NK, Zimmerman M, Larson P, Alvarez-Cabrera N, Park SW, Boshoff HIM, Bean JM, Young VG Jr, Ferguson DM, Dartois V, Jarrett JT, Schnappinger D, Aldrich CC.

ACS Infect Dis. 2019 Apr 12;5(4):598-617. doi: 10.1021/acsinfecdis.8b00345. Epub 2019 Feb 4.

PMID:
30652474
4.

Impact of immunopathology on the antituberculous activity of pyrazinamide.

Blanc L, Sarathy JP, Alvarez Cabrera N, O'Brien P, Dias-Freedman I, Mina M, Sacchettini J, Savic RM, Gengenbacher M, Podell BK, Prideaux B, Ioerger T, Dick T, Dartois V.

J Exp Med. 2018 Aug 6;215(8):1975-1986. doi: 10.1084/jem.20180518. Epub 2018 Jul 17.

Supplemental Content

Loading ...
Support Center